aspirin has been researched along with otamixaban in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frick, A; Gebauer, A; Hesse, G; Hinder, M; Laux, V; Ozoux, ML; Paccaly, A; Rosenburg, R; Scholtz, H | 1 |
| Erdem, G; Flather, MD; Geisler, T | 1 |
1 review(s) available for aspirin and otamixaban
| Article | Year |
|---|---|
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom | 2010 |
1 trial(s) available for aspirin and otamixaban
| Article | Year |
|---|---|
Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Blood Coagulation; Cross-Over Studies; Cyclic N-Oxides; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Male; Pharmacokinetics; Placebos; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyridines | 2006 |